FRM
SNDX icon

Fox Run Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Fox Run Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,993
Closed -$494K – 1275
2026
Q1 		$494K Sell
21,993
-18,309
-45% -$398K 0.09% 445
2025
Q4 		$847K Buy
40,302
+4,646
+13% +$81.1K 0.13% 277
2025
Q3 		$549K Buy
35,656
+17,293
+94% +$226K 0.09% 459
2025
Q2 		$172K Buy
+18,363
New +$202K 0.03% 767
2025
Q1 		– Sell
-16,355
Closed -$216K – 1204
2024
Q4 		$216K Sell
16,355
-13,601
-45% -$233K 0.04% 737
2024
Q3 		$577K Sell
29,956
-25,879
-46% -$535K 0.13% 297
2024
Q2 		$1.15M Buy
+55,835
New +$1.17M 0.22% 139
2023
Q4 		– Sell
-15,320
Closed -$222K – 1002
2023
Q3 		$222K Buy
+15,320
New +$290K 0.07% 534
2023
Q2 		– Sell
-13,214
Closed -$279K – 939
2023
Q1 		$279K Buy
+13,214
New +$329K 0.09% 426

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Fox Run Management's SNDX Position: Q2 2026 in Review

Fox Run Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 21,993 shares — an estimated $494K sold.

Fox Run Management first reported a position in SNDX in Q1 2023 and held it in 9 quarters. The position peaked at $1.15M in Q2 2024. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Fox Run Management reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Fox Run Management sold 21,993 Syndax Pharmaceuticals shares in Q2 2026, an estimated $494K.
  • Fox Run Management first reported a position in Syndax Pharmaceuticals in Q1 2023 and held it in 9 quarters.
  • Fox Run Management's Syndax Pharmaceuticals position peaked at $1.15M in Q2 2024.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.